Crossmark

Use of ceragenins as a potential treatment for urinary tract infections

Crossref DOI link: https://doi.org/10.1186/s12879-019-3994-3

Published Online: 2019-05-02

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wnorowska, Urszula

Piktel, Ewelina

Durnaś, Bonita

Fiedoruk, Krzysztof

Savage, Paul B.

Bucki, Robert http://orcid.org/0000-0001-7664-9226
Funding

Funding for this research was provided by:

Narodowe Centrum Nauki (UMO-2016/21/N/NZ6/02213)

Uniwersytet Medyczny w Bialymstoku (N/ST/ZB/18/005/1162)
License Information

Text and Data Mining valid from 2019-05-02
More Information

Article History

Received: 17 October 2018

Accepted: 15 April 2019

First Online: 2 May 2019

Ethics approval and consent to participate

: This study was approved by the Bioethics Committee at the Jan Kochanowski University in Kielce, Faculty of Medicine and Health Sciences (no. 22/2019).More precisely clinical strains of E. coli were obtained from the hospital collection (Unknown subjects) from the Holy Cross Cancer Centre in Kielce and Independent Public Province Hospital of Jan Sniadecki in Bialystok. Overall the study does not meet the definition of human subject study.

: Not applicable.

: PBS is a paid consultant for N8 Medical, Inc. All other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.